KALEHUA CAPITAL MANAGEMENT LLC
Q3 2026 Form 13-F

DALLAS, DELAWARE
CIK 0002106181 · CRD 325290 · Exempt reporting adviser
$132.4M Reported Value Total
Exempt Reporting Adviser
Source: Form ADV filed 2026-03-31
Reported value
$132.4M
Quarter over quarter
-9.1%
Holdings
22
Top-10 concentration
80.8%

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Tai-Li Chang
Managing Director

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 13, 2026
Form 13F-HR
Reported value $132.4M
Positions 22
Change in reported value -23.9%
New positions 8
Exited positions 12
Position turnover 58.8%
Top-10 concentration 80.8%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 13, 2026
22 $132.4M
Q2 2026 13F
Filed Aug 14, 2026
26 $174.0M
Q1 2026 13F
Filed May 15, 2026
25 $141.3M
Q4 2025 13F
Filed Feb 13, 2026
19 $101.1M

Top 20 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 MANE VERADERMICS INC $17.7M 13.34%
2 BOXX EA SERIES TRUST $17.6M 13.28%
3 KRSA KORSANA BIOSCIENCES INC $14.2M 10.7%
4 XFOR X4 PHARMACEUTICALS INC $10.8M 8.15%
5 ACRS ACLARIS THERAPEUTICS INC $9.6M 7.28%
6 SRZN SURROZEN INC $9.2M 6.95%
7 IKT INHIBIKASE THERAPEUTICS INC $7.9M 5.93%
8 SEPN SEPTERNA INC $7.6M 5.75%
9 BETRF BETTERLIFE PHARMA INC $6.7M 5.04%
10 OBX OBSIDIAN THERAPEUTICS INC $5.7M 4.32%
11 IFRX INFLARX NV $5.3M 3.97%
12 KRRO KORRO BIO, INC $4.7M 3.54%
13 ATTO ATTOVIA THERAPEUTICS INC $3.4M 2.59%
14 DMRA DAMORA THERAPEUTICS INC $3.0M 2.23%
15 QURE UNIQURE NV $1.9M 1.45%
16 GOSS GOSSAMER BIO INC $1.7M 1.25%
17 MIST MILESTONE PHARMACEUTICALS IN $1.4M 1.08%
18 ATHA LEONABIO INC $1.4M 1.06%
19 RNA ATRIUM THERAPEUTICS INC $932.8K 0.7%
20 TIL INSTIL BIO INC $721.1K 0.54%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings